Zylox-Tonbridge Medical Technology Co., Ltd. repurchased 60,000 H shares on 16 June 2026, paying an aggregate HKD 1.13 million at prices between HKD 18.72 and HKD 19.04 per share. The volume-weighted average price was HKD 18.83.

Following the transaction: • Issued shares (excluding treasury shares) decreased 0.018 % to 324.99 million. • Treasury shares rose to 11.36 million, keeping total issued shares unchanged at 336.35 million. • All 60,000 repurchased shares were retained as treasury stock; none were cancelled.

The buyback forms part of a mandate approved on 13 May 2026 that authorises the company to repurchase up to 32.72 million shares. Cumulative repurchases under this mandate now total 2.21 million shares, equivalent to 0.66 % of the share count on the mandate date.

Under Hong Kong listing rules, Zylox-Tonbridge is subject to a moratorium on issuing new shares or selling treasury shares until 16 July 2026.